European Medicines Agency

Doc. Ref. EMEA/310181/2008
P/32/2008

EUROPEAN MEDICINES AGENCY DECISION

of 24 June 2008

on the application for agreement of a Paediatric Investigation Plan for zoledronic acid (Zometa) EMEA-000024-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 24 June 2008

on the application for agreement of a Paediatric Investigation Plan for zoledronic acid (Zometa) EMEA-000024-PIP01-07 in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Novartis Europharm Limited on 26 July 2007 under Article 16(1) of Regulation (EC) No 1901/2006 as amended also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 May 2008, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given a positive opinion.

(2) It is therefore appropriate to adopt a Decision following the Paediatric Committee's opinion on the Paediatric Investigation Plan.

(3) It is therefore appropriate to adopt a Decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for zoledronic acid (Zometa)**,** 4mg powder and solvent for solution for infusion, 4mg/5ml concentrate for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for zoledronic acid (Zometa), 4mg powder and solvent for solution for infusion, 4mg/5ml concentrate for solution for infusion, intravenous use, the details of which are set out in the Opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, Horsham, RH 12 AB.

Done at London, 24 June 2008

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

EMEA/PDCO/224861/2008
EMEA-000024-PIP01-07

POSITIVE OPINION OF THE PAEDIATRIC COMMITTEE ON A REQUEST FOR AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN FOR

Scope of the application

Active substance:
Zoledronic acid

Invented name:
Zometa

Conditions:
Osteogenesis imperfecta
Tumour-induced hypercalcaemia
Prevention of skeletal-related events in patients with advanced malignancies involving bone
Prevention of fracture and bone loss in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors

Pharmaceutical forms:
4mg powder and solvent for solution for infusion
4mg/5ml concentrate for solution for infusion

Route of administration:
Intravenous use

Name/corporate name of the PIP applicant:
Novartis Europharm Limited

Information about the authorised medicinal product: see Annex II

Basis for opinion
Pursuant to Article 16.1 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted for agreement to the EMEA on 26 July 2007 a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 30 August 2007.

Supplementary information was provided by the applicant on 7 March 2008.

A meeting with the Paediatric Committee took place on 7 May 2008.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended and concluded in accordance with Article 11(1)(a) of Regulation (EC) No 1901/2006 as amended, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population Article 11(1)(b) of Regulation (EC) No 1901/2006 as amended, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Icelandic and the Norwegian Paediatric Committee member(s) do agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annexes and appendices.

London, 8 May 2008

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S) / DISEASE(S)

B. WAIVER

- **Condition**
  Osteogenesis imperfecta

    - **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

    The waiver applies to: Preterm and term newborns and infants 28 days to 11 months for 4mg powder and solvent for solution for infusion and 4mg/5ml concentrate for solution for infusion for intravenous use.

- **Condition**
  Tumour-induced hypercalcaemia

    - **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

    The waiver applies to:

    - All paediatric subsets for 4mg powder and solvent for solution for infusion and 4mg/5ml concentrate for solution for infusion for intravenous use.

- **Condition**
  Prevention of skeletal-related events in patients with advanced malignancies involving bone

    - **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

    The waiver applies to:

    - All paediatric subsets for 4mg powder and solvent for solution for infusion and 4mg/5ml concentrate for solution for infusion for intravenous use.

- **Condition**
  Prevention of fracture and bone loss in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors in

    - **Subset(s) of the paediatric population, pharmaceutical form(s) and route(s) of administration covered**

    The waiver applies to:

    - All paediatric subsets for 4mg powder and solvent for solution for infusion and 4mg/5ml concentrate for solution for infusion for intravenous use.

C. PAEDIATRIC INVESTIGATION PLAN

C.1. Condition to be investigated

Osteogenesis imperfecta

- **Subset(s) covered**

Children 1 – 17 years

- **Formulation(s)**

4mg powder and solvent for solution for infusion and 4mg/5ml concentrate for solution for infusion for intravenous use

- **Studies / Measures**

Area	Subarea	Description
Clinical	Efficacy and Safety	Randomised, open-label, multi-center, parallel-group study of zoledronic acid compared to intravenous pamidronate to assess efficacy and safety in children 1-17 years with severe osteogenesis imperfecta
Clinical	PK	Single-dose PK study of zoledronic acid in children with osteogenesis imperfecta 3-17 years of age
Clinical	Long-term efficacy and safety	1 year open-label extension study to assess the safety and efficacy of zoledronic acid in children 1-17 years with severe osteogenesis imperfecta

Need for paediatric measures in a EU-Risk Management Plan: Yes
Date of completion of the paediatric investigation plan: By May 2008
A deferral has been granted*:* No

ANNEX II

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

EU Number[3]	Invented name/ Name	Strength	Pharmaceutical Form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/01/176/001	Zometa	4 mg	Powder and solvent for solution for infusion	Intravenous use	Powder: vial (glass) Solvent: ampoule (glass)	Powder: 4mg Solvent: 5ml	1 vial + 1 ampoule
EU/1/01/176/002	Zometa	4 mg	Powder and solvent for solution for infusion	Intravenous use	Powder: vial (glass) Solvent: ampoule (glass)	Powder: 4mg Solvent: 5ml	4 vial + 4 ampoule
EU/1/01/176/003	Zometa	4 mg	Powder and solvent for solution for infusion	Intravenous use	Powder: vial (glass) Solvent: ampoule (glass)	Powder: 4mg Solvent: 5ml	10 vial + 10 ampoule
EU/1/01/176/004	Zometa	4 mg	Concentrate for solution for infusion	Intravenous use	Vial (plastic)	4mg/5ml	1 vial
EU/1/01/176/005	Zometa	4 mg	Concentrate for solution for infusion	Intravenous use	Vial (plastic)	4mg/5ml	4 vial
EU/1/01/176/006	Zometa	4 mg	Concentrate for solution for infusion	Intravenous use	Vial (plastic)	4mg/5ml	10 vial